

Cutting-Edge Transporter Research Forum in Tokyo
— Exploring Transporters Together: Global Voices, Shared Visions —

Dates: Oct. 27th, 28th 2026

Venue: Kitasato University, School of Pharmacy Convention Hall

PROGRAM

Tuesday, 27th Day 1

9:15 – 9:25 Opening Remarks

Yuichi Sugiyama

GenoMembrane Co., Ltd.

ShanghaiTech University

9:25 – 9:35 Opening Remarks

Sumito Ito

GenoMembrane Co., Ltd.

Symposium 1: **Frontiers in Transporter Science: From Fundamental Discoveries to Future Directions**

9:35 – 10:25 Plenary Lecture

Aleksandra Galetin University of Manchester

Impact of Disease-Driven Alterations in Drug Transporters on Clinical Outcomes and DDIs

10:25 - 11:05 Keynote Lecture

Yuichi Sugiyama

GenoMembrane Co., Ltd.

ShanghaiTech University

Critical Factors for Translating In Vitro Data into PBPK Predictions of Highly Protein-Bound Anionic Drugs

11:05 – 11:35 **Ikumi Tamai**

Emeritus Professor, Kanazawa University

Recent Advances in the Pathophysiology of Uric Acid and Selective URAT1 Inhibitors

11:35 - 12:35 Lunch Break

12:35 - 13:15 Keynote Lecture

Kazuya Maeda

Kitasato University School of Pharmacy

Prediction of the Properties of Intestinal Drug Transport and Metabolism with the Use of Human Crypt-derived Differentiated Intestinal Epithelial Cells

- 13:15 - 13:45 **Tatsuki Mochizuki** Chugai Pharmaceutical Co., Ltd.
Challenges in Overcoming the in Vitro-in Vivo Discrepancy in OATP Inhibition
- 13:45 - 14:15 **Saki Izumi** Eisai Co Ltd
Analysis of OATP1B Inhibition by Cyclosporin A in Humans
Incorporating a Trans-Inhibition Mechanism: Application of Middle Approach Using CGNM
- 14:15 - 14:30 Break
- 14:30 - 15:00 **Yan Zhang** Nuvation Bio
Transporters in ADMET: Key Drivers in Clinical Pharmacokinetics and Drug Development
- 15:00 - 15:30 **Woojin Lee** College of Pharmacy, Seoul National University
Transporters and Stereoselective Disposition of Warfarin in Humans
- 15:30 - 16:00 **Yoshiyuki Shirasaka** Showa Pharmaceutical University
Risk Analysis of Drug-Drug Interactions Considering Gastrointestinal Disposition of P-gp Substrates/Inhibitors
- 16:00 - 16:40 Keynote Lecture
Kousei Ito Graduate School of Pharmaceutical Sciences,
Chiba University
Bile Acid Transporters in Drug-Induced Liver Injury: Contributions to Hepatocellular Death and Inflammation
- 16:40 - 17:20 General Discussion
- 17:40 - 19:40 Banquet
Kitasato University, School of Pharmacy Bldg. No. 2

Wednesday, 28th Day 2

Symposium 2: **Transporter-Mediated DDIs: Endogenous Biomarkers and Bridging In Vitro–In Vivo Gaps**

- 9:00 - 9:40 **Keynote Lecture**
Hiroyuki Kusunohara Graduate School of Pharmaceutical Sciences,
The University of Tokyo
Effects of Cimetidine and Dolutegravir on the Endogenous Drug-Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1
- 9:40 - 10:10 **Xiaoyan Chu** Merck & Co.
Evaluation of the Selectivity of Several Organic Anion Transporting Polypeptide 1B Biomarkers Using Relative Activity Factor Method
- 10:10 - 10:40 **Ryota Kikuchi** AbbVie
Recent Advances in Coproporphyrin-I as a Biomarker for OATP1B-Mediated Drug–Drug Interactions
- 10:40 - 11:10 **Emi Kimoto** Pfizer Inc.
Use of Biomarker-Informed Approach to Support Drug Interaction Risk Assessment
- 11:10 - 11:40 **Shinji Nakayama** Tanabe Pharma Corporation
PBPK Modeling for Investigating the Effect of Simeprevir on Concomitant Drugs and an Endogenous Biomarkers (CP-I and Bilirubin) of OATP1B
- 11:40 - 12:10 **Zhubing Hao** Research Institute for Liver Diseases (Shanghai)
Co., Ltd.
PBPK Modeling Analyses of Letemovir, an Antiviral for Cytomegalovirus Prophylaxis: Middle-Out Approaches to OATP1B-Mediated Nonlinear Pharmacokinetics and Drug-Drug Interactions Using CGNM
- 12:10 - 12:40 **Tadayuki Takashima** Asahi Kasei Therapeutics Corporation
Nonlinear Pharmacokinetics of Endothelin Receptor Antagonists, Bosentan and Tezosentan, Involve Saturable Albumin-Mediated Hepatic Uptake via OATP1B: Top-down and Middle-out Analysis Using CGNM Method Considering In Vitro Human Hepatic Uptake Data

12:40 - 13:40 Lunch Break

Symposium 3: **Role of Transporters in Special Populations: Implications for Clearance and Drug–Drug Interactions**

13:40 - 14:30 Plenary Lecture

Bhagwat Prasad Cincinnati Children's Hospital Medical Center
Opportunities and Challenges in Implementing Drug Transporter Biomarkers for DDI Assessment and Prediction of Pharmacokinetic Variability

14:30 - 15:00 **Toshiaki Tsuchitani** Keio University Faculty of Pharmacy
Characterizing Pharmacokinetics of Apixaban and Edoxaban Through Physiologically-Based Pharmacokinetic Modeling: Importance of Renal Clearance, Biliary Excretion, and Enterohepatic Circulation in Humans

15:00 - 15:30 **Ryuta Asaumi** Astellas Pharma Inc.
Predicting Pharmacokinetics in Cirrhosis: Key Determinants and Their Application to Static and Dynamic (PBPK) Models
– Integrating the Intact Hepatocyte and Sick Hepatocyte Hypotheses –

15:30 - 16:00 **Masanobu Sato** Nippon Boehringer Ingelheim Co., Ltd.
Can the Frequency of Hypoglycemic Events Induced by the Antidiabetic Drug Repaglinide Be Predicted by a PBPK Modeling Approach Considering Drug Interactions and Genetic Variants of OATP1B1? A Comparison with Real-World Data"

16:00 - 16:40 Keynote Lecture

Sumito Ito GenoMembrane Co., Ltd.
Utility of In Vitro Cell-Based Systems for Translational Transporter Research: How should the assumptions underlying the application of the REF method be handled?

16:40 - 17:20 General Discussion

17:20 - 17:30 Closing Remarks

Kazuya Maeda Kitasato University School of Pharmacy